img
Association of PDYN 68-bp VNTR polymorphism with sublingual buprenorphine/naloxone treatment and with opioid or alcohol use disorder: Effect on craving, depression, anxiety and age onset of first use      
Yazarlar
Dilek Akyüzlü
Ankara Üniversitesi, Türkiye
Doç. Dr. Selin ÖZKAN KOTİLOĞLU Doç. Dr. Selin ÖZKAN KOTİLOĞLU
Kırşehir Ahi Evran Üniversitesi, Türkiye
Şafak Yalçın Şahiner
Kütahya Sağlık Bilimleri Üniversitesi, Türkiye
Ece Ağtaş Ertan
Türkiye
İnci İlhan
Ankara Üniversitesi, Türkiye
Özet
In this case-control study (423 Turkish subjects), the functional pro-dynorphin (PDYN) 68-bp VNTR polymorphism was genotyped in opioid users receiving sublingual buprenorphine/naloxone treatment (SBNT; n = 129, 119 males and 10 females), in opioid users (OUD; n = 99, 90 males and 9 females), in alcohol users (AUD; n = 75, 75 males) and in controls (n = 120, 109 males and 11 females) to determine the effect of this polymorphism on different treatment responses, heroin or alcohol dependence as well as age onset of first use. The PDYN 68-bp alleles were determined based on the number of repeats and genotypes were classified as "short/ short (SS) ", "short-long (SL) " and "long-long (LL) ". The intensity of craving, withdrawal, depression and anxiety were measured by the Substance Craving Scale (SCS), the Clinical Opiate Withdrawal Scale (COWS), the Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI), respectively. Healthy controls (5.5 +/- 5.8) had significantly lower levels of depressive symptoms compared to OUD (25.4 +/- 13.5), AUD (22.5 +/- 11.3) and SBNT (19.29 +/- 12.2) groups. In OUD group, the LL genotype was associated with decreased intensity of anxiety and depressive symptoms than the SS+SL genotype. The BDI-II scores for PDYN VNTR genotypes within the 4 groups were analysed by two-way ANOVA and statistical differences were found for the groups. SBNT group had significantly lower COWS score than OUD group (1.00 versus 3.00). There were statistically significant differences in the median BAI (11 versus 24) and BDI-II scores (17.5 versus 25) between OUD and SBNT groups, supporting the antidepressant and anxiolytic effects of SBNT in persons with OUD.
Anahtar Kelimeler
Alcohol | Heroin | Buprenorphine | PDYN 68-bp VNTR | Age onset of first use
Makale Türü Özgün Makale
Makale Alt Türü SSCI, AHCI, SCI, SCI-Exp dergilerinde yayımlanan tam makale
Dergi Adı EUROPEAN JOURNAL OF PHARMACOLOGY
Dergi ISSN 0014-2999
Dergi Tarandığı Indeksler SCI-Expanded
Dergi Grubu Q1
Makale Dili İngilizce
Basım Tarihi 04-2022
Cilt No 921
Sayfalar 174862 /
Doi Numarası 10.1016/j.ejphar.2022.174862
Makale Linki http://dx.doi.org/10.1016/j.ejphar.2022.174862